Y-mabs announces third quarter financial results and recent corporate developments

New york, nov. 04, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2021.

YMAB Ratings Summary

YMAB Quant Ranking